File Download

There are no files associated with this item.

  • Find it @ UNIST can give you direct access to the published full text of this article. (UNISTARs only)
Related Researcher

김홍태

Kim, Hongtae
Cancer/DNA damage Lab.
Read More

Views & Downloads

Detailed Information

Cited time in webofscience Cited time in scopus
Metadata Downloads

Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia

Author(s)
Kee, Kyung-MiKim, Soo-HyunYang, Seon-YoungShin, Jeong-UNam, Yoon-WonJang, Eun-JungKim, HongtaeLee, SeminPark, Sung HoKim, Dong-Wook
Issued Date
2022-01
DOI
10.1016/j.leukres.2021.106754
URI
https://scholarworks.unist.ac.kr/handle/201301/56564
Fulltext
https://www.sciencedirect.com/science/article/pii/S0145212621017550?via%3Dihub
Citation
LEUKEMIA RESEARCH, v.112, pp.106754
Abstract
To compare the clinical significance of 3-month cytogenetic and molecular monitoring, we analyzed 1,410 paired cytogenetic and molecular data from 705 chronic-phase chronic myeloid leukemia patients. Based on early cytogenetic response (ECyR, Ph+≤35 %) and molecular response (EMR, BCR-ABL1IS≤10 %) at 3 months, the patients were divided into four groups (group 1: ECyR + EMR, n = 560; group 2: no ECyR + EMR, n = 27; group 3: ECyR + no EMR, n = 55; group 4: no ECyR + no EMR, n = 63). By 10 years, major molecular response (MMR), deep molecular response (MR4.5), overall survival (OS), and progression-free survival (PFS) rates were significantly high in group 1 (P < 0.001). Comparing groups 2 and 3, the MMR (P = 0.096), MR4.5 (P = 0.945), OS (P = 0.832), and PFS (P = 0.627) rates tended to be higher in group 2, although not significantly. Thus, the cytogenetic assay can not only be useful but its addition may also provide a more precise prediction of MR4.5.
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
ISSN
0145-2126
Keyword (Author)
Chronic myeloid leukemiaEarly responseCytogenetic responseMolecular responseTyrosine kinase inhibitor
Keyword
POLYMERASE-CHAIN-REACTIONBCR-ABLTRANSCRIPT LEVELSIMATINIB MESYLATEPHASEINTERFERONPREDICTSDASATINIBCMLACHIEVEMENT

qrcode

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.